AfricaRegulatory
African Pharmaceutical Regulatory Intelligence
LENACAPAVIR
5 registrations across 3 African markets— 5 active
Markets with LENACAPAVIR
Recent registrations
| Brand / Product | Market | Holder | Status | Expires |
|---|---|---|---|---|
| Lenacapavir Gilead 300 mg film-coated tablets Film-Coated Tablet | 🇰🇪Kenya | Gilead Sciences Ireland UC | active | Jan 2031 |
| LENACAPAVIR GILEAD TABLET, COATED; ORAL | 🇿🇼Zimbabwe | GILEAD SCIENCES IRELAND UC, | active | Nov 2030 |
| LENACAPAVIR GILEAD SOLUTION; INJECTION | 🇿🇼Zimbabwe | GILEAD SCIENCES IRELAND UC, | active | Nov 2030 |
| Lenacapavir Tablet, Film-coated 300mg Tablet, Film-coated | 🌍WW | Gilead Sciences Ireland UC | active | — |
| Lenacapavir Solution for injection 463.5 mg/1.5 mL Solution for injection | 🌍WW | Gilead Sciences Ireland UC | active | — |
LENACAPAVIR in Africa — Regulatory Overview
LENACAPAVIR is registered across 3 African markets with 5 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including WW, Zimbabwe, Kenya. AfricaRegulatory refreshes this data daily from official government sources.
Of the 5 registrations, 5 (100%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.